2023 World Conference on Lung Cancer (Posters)-P2.12. Phase II Trial of LP-300 + Pemetrexed/Carboplatin in Patients Who Never Smoked with Lung Adenocarcinoma After TKI Progression

P2.12. Phase II Trial of LP-300 + Pemetrexed/Carboplatin in Patients Who Never Smoked with Lung Adenocarcinoma After TKI Progression - PDF(Abstract)

Back to course

Pdf Summary

This document presents information about a phase II clinical trial evaluating the efficacy of LP-300, a targeted therapy, in patients with metastatic non-small cell lung cancer (NSCLC) who have never smoked. LP-300 is a multi-targeting modulator that works by inactivating tumor-driving oncogenes and sensitizing the cells to chemotherapy. Previous trials have shown that LP-300 has a survival benefit in patients who never smoked, especially women. The objective of this trial, called The HARMONICTM Study, is to validate the effectiveness of LP-300 with pemetrexed/carboplatin compared to pemetrexed/carboplatin alone in patients with lung tumors possessing actionable genomic alterations (EGFR, ALK, ROS1, MET exon14 skipping, BRAF, NTRK) who have experienced tyrosine kinase inhibitor (TKI) progression or intolerance. The primary endpoints of the trial are progression-free survival and overall survival. To be eligible for the trial, patients must be never smokers, meaning they have smoked fewer than 100 cigarettes in their lifetime. Enrollment for this trial began in March 2023. The results of this trial will help determine the efficacy and potential use of LP-300 in treating NSCLC patients who have never smoked.

Asset Subtitle

Joseph Treat

Meta Tag

Speaker Joseph Treat

Topic Metastatic NSCLC: Targeted Therapy - Other

Keywords

LP-300

non-small cell lung cancer

never smoked

multi-targeting modulator

chemotherapy

The HARMONICTM Study

genomic alterations

tyrosine kinase inhibitor

progression-free survival

overall survival